IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by D.A. Davidson & CO.

D.A. Davidson & CO. cut its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 21.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,421 shares of the medical research company’s stock after selling 5,455 shares during the quarter. D.A. Davidson & CO.’s holdings in IQVIA were worth $3,816,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. Private Trust Co. NA grew its position in shares of IQVIA by 10.7% in the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 47 shares during the last quarter. Clear Harbor Asset Management LLC grew its position in shares of IQVIA by 1.3% in the third quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock valued at $941,000 after purchasing an additional 50 shares during the last quarter. Pine Valley Investments Ltd Liability Co grew its position in shares of IQVIA by 0.5% in the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after purchasing an additional 50 shares during the last quarter. Fortitude Family Office LLC grew its position in shares of IQVIA by 2.9% in the third quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company’s stock valued at $468,000 after purchasing an additional 56 shares during the last quarter. Finally, Huntington National Bank grew its position in shares of IQVIA by 7.4% in the third quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock valued at $192,000 after purchasing an additional 56 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on IQV. Stifel Nicolaus reduced their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. TD Cowen reduced their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. William Blair reissued an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Robert W. Baird reduced their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Finally, BTIG Research downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $251.22.

IQVIA Price Performance

IQV opened at $194.01 on Friday. The company has a fifty day simple moving average of $199.86 and a 200 day simple moving average of $216.95. The firm has a market cap of $34.16 billion, a price-to-earnings ratio of 25.87, a PEG ratio of 1.98 and a beta of 1.48. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities research analysts expect that IQVIA Holdings Inc. will post 10.86 EPS for the current fiscal year.

Insider Activity at IQVIA

In other news, Director John G. Danhakl purchased 1,275 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, with a total value of $255,739.50. Following the acquisition, the director now owns 1,275 shares in the company, valued at approximately $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.